Kari Wisinski, MD
Enriched profileChief, Division of Hematology, Medical Oncology and Palliative Care; Professor (Endowed Professor of Hematology and Oncology) · University of Wisconsin-Madison
Kari Wisinski is Chief, Division of Hematology, Medical Oncology and Palliative Care; Professor (Endowed Professor of Hematology and Oncology) at University of Wisconsin-Madison. OpenAlex indexes 261 publications with 7,339 citations (h-index 35); ClinicalTrials.gov lists 18 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 1 Sept 2026
Kari Wisinski, MD, is Chief, Division of Hematology, Medical Oncology and Palliative Care at University of Wisconsin-Madison, Department of Medicine / UW Carbone Cancer Center. The public record shows 261 publications with 7,339 citations (h-index 35), centered on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 8 companies, 2 NIH-funded awards (2022–2026).
- Top research focus: Advanced Breast Cancer Therapies
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 59.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
Sponsor: University of Wisconsin, Madison
- Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
- Study of 18F-FFNP Breast PET/MRI
Sponsor: University of Wisconsin, Madison
Industry payments
Updated 1 Sept 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20256 payments
- Gilead Sciences, Inc.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.7%Aromatase Inhibitor56.1%Anastrozole67%Letrozole24%Exemestane9%Part D<11 patientsKinase inhibitor12.6%Verzenio48%Ibrance37%Kisqali16%Part D<11 patientsMetabolism & gastrointestinal
9.2%Serotonin-3 Receptor Antagonist9.2%Ondansetron Hcl100%Part D≥23 patientsNervous system
8.7%Opioid Agonist3.6%Oxycodone Hcl100%Part D<11 patientsPhenothiazine3%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- National Clinical Trials Network Research at the University of Wisconsin
University of Wisconsin-Madison
FY2026$648,001UG1CA233277 - National Clinical Trials Network Research at the University of Wisconsin
University of Wisconsin-Madison
FY2025$531,249UG1CA233277
Congress activity
Updated 1 Sept 2026
66 congress contributions (2008–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 4308: BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Journal of the National Comprehensive Cancer Network
2025 - Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Journal of the National Comprehensive Cancer Network
2023
Most-cited works
by citation count (OpenAlex)- 01
- 02Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle971 citations2022
- 03Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyArticle598 citations2024
- 04
- 05NCCN Guidelines® Insights: Breast Cancer, Version 4.2023Article449 citations2023
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/kari-wisinski-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Bluesky
bsky.app/profile/kariwisinskimd.bsky.social
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bsky.app ↗ - ResearchGate
researchgate.net/profile/Kari-Wisinski
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/UWCarbone/posts/10157699859742536
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
bigtencrc.org/leadership/kari-wisinski
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bigtencrc.org ↗ - Other
uwhealth.org/providers/kari-b-wisinski-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uwhealth.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Washington University School of Medicine, St. Louis, MO
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - Internal Medicine residency
University of Colorado Health Sciences Center, Denver, CO
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - Hematology/Oncology fellowship
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sharecare.com ↗
Editorial & leadership roles
journal and society appointments- Deputy Editor
Clinical Breast Cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clinical-breast-cancer.com ↗ - Member and past chair
Big Ten Cancer Research Consortium Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - Co-chair
Breast Cancer Clinical Trial Working Group, Big Ten Cancer Research Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.wisc.edu ↗
Awards & honors
honors on the public record- 2024 Pat Loehrer Award for Exemplary Collaboration in Cancer Research
Big Ten Cancer Research Consortium
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bigtencrc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.wisc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
Media & interviews
press, podcasts and appearances- Video interview series on OncLive discussing treatment developments in HR+/HER2- breast cancer
palbociclib for metastatic breast cancer, and genomic predictors in breast cancer chemotherapy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles